Ghassan Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.

Ghasson K. Abou-Alfa, MD, discusses that phase 2 study of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma.

Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.

Ghassan Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses the important role that locoregional therapy plays in the treatment of liver cancer.

Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.